Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07221578 · ClinicalTrials.gov registry record · Phase 3

Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder

A Phase 3 study of Social Anxiety Disorder (SAD), sponsored by Vanda Pharmaceuticals.

Recruiting
Registry status
Phase 3
Development phase
500
Enrollment target
20
Study locations

NCT07221578 is a Phase 3 study of Social Anxiety Disorder (SAD) that is actively recruiting participants, run by Vanda Pharmaceuticals. The registered enrollment target is 500 participants, above the 103-participant average among 5 other Social Anxiety Disorder (SAD) trials with a reported enrollment target (385% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07221578, a Phase 3 study of Social Anxiety Disorder (SAD), is actively recruiting participants, sponsored by Vanda Pharmaceuticals.

RECRUITING
Registry status
Phase 3
Development phase
500 participants
Enrollment target
20
Study locations

Study Summary

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.

Conditions Studied

Social Anxiety Disorder (SAD)

Interventions

  • DRUG Placebo
  • DRUG VQW-765

Study Locations (20)

California

  • Vanda Investigational Site - Encino
  • Vanda Investigational Site - Newport Beach
  • Vanda Investigational Site - San Diego
  • Vanda Investigational Site - San Jose
  • Vanda Investigational Site - Walnut Creek

Florida

  • Vanda Investigational Site - Jacksonville
  • Vanda Investigational Site - Miami
  • Vanda Investigational Site - Orlando
  • Vanda Investigational Site - Tampa

Arizona

  • Vanda Investigational Site - Phoenix
  • Vanda Investigational Site - Scottsdale

Georgia

  • Vanda Investigational Site - Atlanta
  • Vanda Investigational Site - Suwanee

Maryland

  • Vanda Investigational Site - Pikesville
  • Vanda Investigational Site - Rockville

Missouri

  • Vanda Investigational Site - Saint Charles
  • Vanda Investigational Site - St Louis

Colorado

  • Vanda Investigational Site - Denver

Louisiana

  • Vanda Investigational Site - New Orleans

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2025-09-22
Est. Completion 2027-04
Phase Phase 3

Sponsor

Vanda Pharmaceuticals

68 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07221578

The ClinicalTrials.gov registry entry for NCT07221578 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 103-participant average among 5 other Social Anxiety Disorder (SAD) trials with a reported enrollment target (385% higher). The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Social Anxiety Disorder (SAD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07221578 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT07221578 about?

NCT07221578 is a clinical study titled "Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder". This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.

What is the current status of trial NCT07221578?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2025-09-22. Estimated completion is 2027-04.

What conditions does trial NCT07221578 study?

This clinical trial studies the following conditions: Social Anxiety Disorder (SAD).

What interventions are being tested in trial NCT07221578?

The interventions under investigation include: Placebo (DRUG), VQW-765 (DRUG).

Who is sponsoring clinical trial NCT07221578?

This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07221578 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Social Anxiety Disorder (SAD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Social Anxiety Disorder (SAD)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.